Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Before the Big Freeze, Neurizon delivers warm hope by advancing MND treatment | 2 | Stockhead | ||
Mo | NEURIZON THERAPEUTICS LIMITED: Change of Registered Office and Principal Place of Business | 2 | ASX | ||
14.05. | NEURIZON THERAPEUTICS LIMITED: Neurizon to present at Annual ALS Drug Development Summit | 2 | ASX | ||
06.05. | NEURIZON THERAPEUTICS LIMITED: Neurizon to present Q3 FY2025 Results | - | ASX | ||
05.05. | NEURIZON THERAPEUTICS LIMITED: Last Patient Successfully Completes Treatment in OLE Study | 3 | ASX | ||
28.04. | NEURIZON THERAPEUTICS LIMITED: Appendix 4C & Quarterly Update | 2 | ASX | ||
NEURIZON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
24.04. | NEURIZON THERAPEUTICS LIMITED: Notice of Quarterly Shareholder Update Webinar | 2 | ASX | ||
22.04. | NEURIZON THERAPEUTICS LIMITED: Appointment of Chief Financial Officer | 2 | ASX | ||
17.04. | Neurizon Adds Strategic Regulatory and Scientific Leadership | 4 | Contract Pharma | ||
17.04. | NEURIZON THERAPEUTICS LIMITED: Leadership team strengthened with strategic appointments | 1 | ASX | ||
14.04. | Neurizon Therapeutics announces strong safety results in latest study | 4 | The Market Herald Australia | ||
07.04. | Neurizon confirms lead drug NUZ-001 has neuroprotective potential | 4 | Stockhead | ||
04.04. | HotCopper Highlights for Week 14 - Mesoblast, Cettire, Neurizon & more! | 2 | The Market Herald Australia | ||
04.04. | NEURIZON THERAPEUTICS LIMITED: NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells | 5 | ASX | ||
02.04. | Neurizon Therapeutics Reports Positive NUZ-001 Study | 3 | Finance News Network | ||
01.04. | StockTake: Neurizon's lead asset shows positive results in latest study | 2 | Stockhead | ||
01.04. | Neurizon Therapeutics reports positive study results on human brain model by neuroprotective candidate NUZ-001 | 1 | smallcaps.com.au | ||
01.04. | StockTake: Neurizon's potential cure for Alzheimer's | 2 | Stockhead | ||
01.04. | Neurizon finds positive results for lead drug in 3D brain model study | 2 | The Market Herald Australia | ||
01.04. | NEURIZON THERAPEUTICS LIMITED: NUZ-001 Shows Positive Results in Human 3D Brain Model | 2 | ASX |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,510 | +0,15 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer anlässlich der Asco-Krebsforschertagung mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Die Onkologie-Pipeline... ► Artikel lesen | |
NOVARTIS | 103,76 | +0,12 % | Märkte am Morgen: Lanxess, Öl, Roche, Novartis, Rheinmetall, Hensoldt, Renk | Der Mai gilt eigentlich als schlechter Börsenmonat. In diesem Jahr wurde er seinem Ruf allerdings nicht gerecht. Der DAX legte im Mai 6,7 Prozent zu, mehrere Allzeithochs inklusive. Heute dürfte der... ► Artikel lesen | |
GILEAD SCIENCES | 98,80 | +0,13 % | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
ROCHE | 285,50 | -0,21 % | Roche's Evrysdi tablets granted EC approval to treat spinal muscular atrophy | ||
STADA ARZNEIMITTEL | - | - | MIDDAY BRIEFING - Unternehmen und Märkte: HELLOFRESH, STADA, BRITISH AMERICAN TOBACCO, JULIUS BÄR, TOYOTA, TSMC | DJ MIDDAY BRIEFING - Unternehmen und Märkte
Der Markt-Überblick am Mittag, zusammengestellt von Dow Jones Newswires:
+++++ FEIERTAGSHINWEIS +++++
DIENSTAG: In Seoul findet wegen des Feiertages... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
TEVA | 15,250 | -2,24 % | Teva Pharmaceutical: Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building | NORTHAMPTON, MA / ACCESS Newswire / June 6, 2025 / Teva Pharmaceutical:At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients... ► Artikel lesen | |
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 7,718 | -1,56 % | EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration | - Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 30,650 | +0,46 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 4,600 | +0,97 % | Green Thumb Industries Inc: Green Thumb to hold cannabis, music festival | ||
SINOPHARM | 2,110 | +0,19 % | Kurs der Sinopharm Group fällt ab (2,054 €) | Am Aktienmarkt notiert der Anteilsschein der Sinopharm Group aktuell ein wenig leichter. Die Aktie notiert derzeit bei 2,05 Euro. Für Inhaber der Sinopharm Group ist der heutige Handelstag bisher nicht... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 14,200 | 0,00 % | Assembly Biosciences: "Es ist ein großes Jahr für uns" | Mein Top-Favorit 2025 setzt zur Rallye an: +90% Kursgewinn innerhalb der letzten zwei Monate können erst der Anfang sein. Assembly Biosciences (WKN: A402CB) steht vor entscheidenden sechs Monaten. Sämtliche... ► Artikel lesen | |
INDIVA | 0,016 | -100,00 % | Indiva Ltd: Indiva to be delisted from NEX |